Neurocure
Incorporation
Partnership and Investment Oppurtunities
At Neurocure Inc., we are at the forefront of revolutionizing regenerative medicine with our groundbreaking product, RAXON. By partnering with us, you’ll join a mission to transform healthcare and improve the lives of millions of patients worldwide. Here’s why partnering with us is a unique opportunity:
Massive Market Opportunity:
The global regenerative medicine market is projected to grow from $40 billion in 2023 to over $100 billion by 2030, with a CAGR of 10-25%.
RAXON addresses a $4 billion market in stroke and traumatic brain injury (TBI) treatment alone, with additional applications in osteoarthritis, sports injuries, and skin rejuvenation.
Proven Competitive Advantages:
Innovative Technology: RAXON is a first-of-its-kind device that combines tPA with regenerative properties, addressing a critical gap in stroke and TBI treatment.
Patent-Pending:
Our proprietary method for preparing Autologous Conditioned Serum (ACS) and Platelet-Rich Plasma (PRP) is patent-pending in Canada (CIPO Application No. 3,219,280).
Versatile Applications:
RAXON is effective in treating a wide range of degenerative and inflammatory conditions, making it a versatile solution for multiple markets.
Transformative Social Impact:
RAXON has the potential to improve the quality of life for millions of patients suffering from stroke, TBI, osteoarthritis, and other degenerative conditions. By promoting natural healing and reducing long-term disability, RAXON addresses a critical unmet need in global healthcare.
We are actively seeking partnerships to accelerate the development, regulatory approval, and commercialization of RAXON. Here are the types of partnerships we’re looking for:
Partner with us to conduct clinical trials and validate RAXON’s efficacy in treating stroke, TBI, and other conditions.
Investing in Neurocure Inc. means investing in the future of regenerative medicine. Here’s what you need to know:
We project $1.5 million in revenue by 2031, with a 50% gross margin and 45% net margin by 2028.
Our value-based pricing strategy of $2,000 per kit ensures strong profitability and scalability.